Summary Report of Consolidated Financial Results
For the Six Months Period ended September 30, 2014
November 12, 2014stCompany name: NIPRO CORPORATION
TSE-1 section
Code No.8086
URL: http://www.nipro.co.jp/
Representative: Yoshihiko Sano, President and Representative Director
Contact person: Kimihito Minoura, Director and General Manager of Corporate Planning Headquarters
TEL: (06)6372-2331
Filing date of quarterly reporting: November 14, 2014
Payment date of cash dividends: December 9, 2014
Supplemental material on quarterly reporting: Yes
Presentation on quarterly results: Yes (for institutional investors and analysts)(Note: Amounts are truncated to one million yen)
1. Consolidated Results for the Six Months ended September 30, 2014 (From April 1, 2014 to September 30, 2014)(1) Consolidated Results of Operations(Note: % of change from the same period a year ago)
Net Sales
Operating Income
Ordinary Income
Net Income
Millions of yen% Millions of yen% Millions of yen% Millions of yen%
6 months ended September 30, 2014
154,501
7.7
7,939
36.9
8,618
48.9
5,470
108.8
6 months ended September 30, 2013
143,407
22.3
5,797
(8.0)
5,787
19.5
2,619 (60.4)
Note: Comprehensive income

6 months ended September 30, 2014: (209) million yen (-%)

6 months ended September 30, 2014
6 months ended September 30, 2013

Earnings per share
Yen
36.28
15.99

(2) Consolidated Financial Position
Total Assets
Millions of yen
6 months ended September 30, 2014
633,574
Year ended March 31, 2014
619,654
Note: Equity

2.

6 months ended September 30, 2013: 26,025 million yen (-%)

Diluted Earnings per share
Yen
32.34
14.38

Net Assets
Millions of yen
136,029
135,960

6 months ended September 30, 2014: 125,560 million yen

Equity Ratio
%
19.8
20.2

Year ended March 31, 2014: 125,426 million yen

Dividends

Year ended March 31, 2014
Year ending March 31, 2015
Year ending March 31, 2015
(Forecast)

Annual Dividends per Year
Year-end Dividends
Second-quarter
Third-quarter
Yen
Yen
Yen
16.00
14.50
18.00

First-quarter
Yen
-

-

Annual Dividends

Yen
30.50

14.50

32.50

Note: Revisions to the forecast of cash dividends in the current quarter: Yes
3.

Forecast of Consolidated Financial Results for the Year ending March 31, 2015 (From April 1, 2014 to March 31, 2015)(Note: The % displays in the line of year ending March 31, 2015 show increase/decrease ratio against the year ended March 31, 2014)

Operating
IncomeNet Sales
Millions of yen%

Millions of yen

Ordinary Income%

Millions of yen%

330,000 9.7
20,00062.7
18,60056.1
Note: Revisions to the forecast of consolidated financial results in the current quarter: Yes
Year ending March 31, 2015

Net Income
Millions of yen

10,400%263.4

Earnings
per Share
Yen
68.97

*Notes(1) Change in Significant Subsidiaries during the Current Period(Change in specified subsidiaries caused a change in the scope of consolidation): No
Additional: 0Removal: 0(2) Adoption of Accounting Treatments Simplified or Unique for Preparation: No(3) Change in Accounting Policies and Accounting Estimate and Restatement[1] Changes in accounting policies by a newly issued accounting pronouncement: Yes[2] Changes other than [1]: No[3] Change in accounting estimate: No[4] Restatement: No
Note: More information can be found in P.4 “2. Summary (Other) Information, (3) Changes in Accounting Policies andAccounting Estimate and Restatement” in the attachment.
(4) Issued Shares (Common stock)[1] Number of issued shares at end of the period (including treasury stock):
6 months ended September 30, 2014: 171,459,479 sharesYear ended March 31, 2014: 171,459,479 shares[2] Number of treasury stock at end of the period:
6 months ended September 30, 2014:

17,556,287 sharesYear ended March 31, 2014:

20,730,973 shares[3] Average number of shares during the period:
6 months ended September 30, 2014: 150,792,006 shares

6 months ended September 30, 2013: 163,829,523 shares

Note: Number of the treasury stocks as of September 30, 2014 included 1,067,900 shares, and as of March 31, 2014
included 1,187,500 shares owned by Trust Account E*Information regarding the quarterly review procedure
This quarterly summary report is exempt from quarterly review procedure based on the Financial Instruments
and Exchanges Act. It is under the review procedure process at the time of disclosure of this report.
*Disclaimer regarding projection information including appropriate use of forecasted financial result, and otherspecial notes
The projection figures shown above are based on information that was available at the time of preparation and may
contain certain uncertainties. Actual performance and other factors may differ from these projections due tochanges in circumstances and other developments. More information concerning these forecasts can be found in P.4“1. Qualitative Information for the Six-Month Period Ended September 30, 2014, (3) Commentary on
Forward-Looking Statements Including Forecast of Consolidated Financial Results” in the attachment.

Table of Contents

1.

2.

3.

Qualitative Information for the Six-Months Period ended September 30, 20142

(1) Commentary on Business Results

2(2) Analysis Concerning Financial Position

3(3) Commentary on Forward-Looking Statements Including Forecast of Consolidated Financial Results

4

Summary (Other) Information

4(1) Changes in Significant Consolidated Subsidiaries

4(2) Accounting Treatments Simplified or Unique for Preparation

4(3) Changes in Accounting Policies and Accounting Estimate and Restatement

4

Consolidated Financial Statements

6(1) Quarterly Consolidated Balance Sheets

6(2) Quarterly Consolidated Statements of Income andQuarterly Consolidated Statements of Comprehensive Income

8

Quarterly Consolidated Statements of Income

8

Quarterly Consolidated Statements of Comprehensive Income

8

Quarterly Consolidated Statements of Cash Flows

9(3) Notes Regarding Consolidated Financial Statement

11

Notes regarding going concern

11

Notes regarding significant changes in the amount of shareholders’ equity

11

Segment Information

11

-1-

1. Qualitative Information for the Six-Month Period Ended September 30, 2014
(1) Commentary on Business Results
During the six months of the fiscal year under review, the global economy generally remained on a gradual recovery
trend while an improvement in personal consumption could not lead significant recovery in the United States and Europe
showed signs of partial economic recovery in unstable situation with political unrest of Ukraine. In China and emerging
countries, a sense of uncertainty is increasing due to declining economic growth rates. On the other hand, the Japanese
economy showed continued improvement although there were a rapid yen depreciation and a fallback after thelast-minute surge in demand before the consumption tax rate hike and.
Under such circumstances, the Nipro Group has worked to improve operating results through its continued efforts to
expand sales and reduce costs.
As a result, consolidated sales for the six-month period ended September 30, 2014 increased by 7.7% from the same
period of the previous year to 154,501 million yen. As for the profit, consolidated operating income increased by 36.9%
from the same period of the previous year to 7,939 million yen. Consolidated ordinary income, moreover, increased by
48.9% from the same period of the previous year to 8,618 million yen due to the foreign exchange gain for yen’s
depreciation. Consolidated net income increased by 108.8% from the same period of the previous year to 5,470 million
yen thanks to the record of gain on sales of investment securities.
The overview of the results for the current quarter period under review by business segment is as follows.
Effective from this reporting period, overseas glass department is reclassified from Medical-Related Business to
Glass-Related Business with the current classification.

(i)

Medical-Related BusinessLooking at the domestic market, the Medical Sales Division largely increased sales and profits of the drug-eluting

balloon catheter “SeQuent® Please” in the field of vascular products and they also show strong sales of HDF filter withdiffusion of on-line HDF treatment. On the other hand, sales and profits of the cardiovascular (CVS) products were in the
midst of the severe environment where a competitor's ventricular assisting device was launched into the market and newclinical trials were started by other companies. As a whole, the sales and profit was continuously sluggish due to therevision of medical fees and drug prices and the fallback after the special demand arose before the consumption tax rate
hike. The Pharmaceutical Sales Division gained solid net sales thanks to an increase in newly adopted drugs particularly
for oral and external use. This is partly because hospitals subject to diagnosis procedure combination (DPC) anddispensing pharmacies promoted a switch to generic drugs following the revision of medical fees led by the government’s
generic drug promotion measures. Such development offset a decline in unit prices of drugs due to a revision of theirwholesale prices (selling prices to wholesale dealers) following the revision in drug prices in April 2014. However, large
markets of new big listing items have being continuously entered by over 30 competitors and initial sales of AG(authorized generic) allows to market occupation, that made the market price competition more intensified to impact
significantly to sales and profit.
Regarding overseas sales, on the other hand, direct sales activities were promoted with enhancement of overseas
sales channel based on our concept of “local production for local consumption” and expanded our sales responding
immediately to demand from medical front. In addition, sales prices were reviewed throughout the world to improve our
profitability. Furthermore, yen’s depreciation against dollar and euro in foreign exchange market increasing export
profitability resulted double-digit growth in sales and profit from the same period of the previous year. By product, wehave promoted academic activities through international societies or exhibition of dialysis or kidney disease as well as
enhanced dialysis product line, and consequently sales of the related products such as artificial kidneys (dialyzers)
showed a strong increase. New overseas plants (in India, Indonesia and Bangladesh) further improved their production
system and realized stable production expansion under established quality system to promote their sales widely in theircountries and surrounding areas. Especially sales of syringe have grown by double-digit rate from the same period of theprevious year thanks to expansion of production in new overseas plant, India and Indonesia.
As a result, net sales of this business increased by 7.0% from the same period of the previous year to 112,538 million
yen.

-2-

(ii)

Pharmaceutical-Related BusinessIn the Pharmaceutical-Related Business, we have promoted finely-tuned sales activities to win contracted businesses

by offering various contracted services such as contracted development based on our characteristic of development andsupply from packaging container such as vial, syringe and bag and support for value adding initiatives, in addition to ourconventional contracted manufacturing service. We have also worked to expand the contracted manufacturing businessthrough joint development with generic drug divisions and new drug development divisions of leading pharmaceuticalmanufacturers inside and outside of Japan. Furthermore, the self-developed blockbuster syringe preparations, shipmentof which started at the end of the previous fiscal year, contributed to the solid sales of this segment.
Sales of pharmaceutical containers as well as devices related to pharmaceutical preparation and administration werestrong thanks to our efforts to offer containers and systems suitable to each pharmaceutical product. Such efforts weremade to meet various needs in the medical front, including small-volume bags for antimicrobial agents and osteoporosis
drugs, materials for pre-filled syringes (plastic and glass), etc., on top of rubber stoppers for pharmaceutical and vaccine
use and containers for kit products. We developed the containers and systems by ourselves or through joint developmentwith pharmaceutical manufactures based on our processing technologies for plastics, rubbers, and metals. In addition,
under the government’s policy to curb medical expenses, we have worked together with domestic and foreign
pharmaceutical manufactures in enhancing comprehensive lifecycle management of pharmaceutical products, taking into
consideration the development of combination products, self-injection systems, and dosage form/administrating pathmodification in the future.
As a result, net sales of this business increased 14.5% from the same period of the previous year to 27,775 million yen.

(iii) Glass-Related BusinessIn the Glass-Related Business, adding to our conventional glass containers for medical use, we have developed
high-value added vials to support diverse injectable formulation with a high level of quality requirements to acquire new
demand and global customer’s needs. We also improved our manufacturing facilities and environment for the stablesupply of these products.
In domestic glass department, we have promoted our sales activity for the processing technique of vials with low alkali
elution to the medical and pharmaceutical industries. Meanwhile, we also started full-scale operation of the “Biwako
Factory,” a state-of-the-art plant for glass containers for domestic medical use, with the purpose of further improving ourquality assurance system for good manufacturing practice (GMP). Under the system, we have established the production
and sales setup enabling the stable supply of high-quality and eco-friendly glass containers for medical use required bypharmaceutical manufacturers. Among other glass-related products, sales of automotive electric bulbs showed a solid
growth partially due to the effect of quality improvement, while sales of glass for thermos bottles decreased from the same
period of the previous year due to weak domestic demand against the recovery of export. Whole sales of this department
slightly decreased but sales of vial for medical purpose, especially high-valued vial such as large vial, increased thanks tothe acquisition of new demand.
Regarding overseas glass department, on the other hand, sales and profit of vial and ampoule have increased stably in
India and China under the changing of market that requires high-quality medical containers in developing countries. In
Europe and the United States, high-tech prefilled syringe has marked find sales.
As a result, net sales of this business increased 1.8% from the same period of the previous year to 14,124 million yen.

(iv) Other BusinessAmong other business, sales from the real-estate rental business were 63 million yen (down by 46.0% from the same
period of the previous year).

(2) Analysis Concerning Financial Position[1]Analysis Concerning the Conditions of Assets, Liabilities and Net Assets
Total assets increased by 13,919 million yen from the end of the previous year to 633,574 million yen. Current assets
increased by 20,113 million yen primarily due to an increase of 14,914 million yen in cash and deposits, and noncurrent
assets decreased by 6,193 million yen primarily due to a decrease of 6,967 million yen in other of investment and otherassets.

-3-

Total liabilities increased by 13,850 million yen from the end of the previous year to 497,544 million yen. Current
liabilities decreased by 16,027 million yen primarily due to an decrease of 6,175 million yen in income taxes payable, andnoncurrent liabilities increased by 29,877 million yen primarily due to an increase of 31,313 million yen in long-term loans
payable.
Total net assets increased by 69 million yen from the end of the previous year to 136,029 million yen. Shareholders’equity increased by 5,622 million yen and accumulated other comprehensive income decreased by 5,489 million yen.
[2] Condition of cash flow
The ending balance of cash and cash equivalents in the period under review increased 14,480 million yen from theprevious year to 85,372 million yen.
(Cash flows from operating activities)
Net cash provided by operating activities was 2,476 million yen. The main accounts of cash inflow were income before
income taxes and minority interests, 10,796 million yen and depreciation and amortization, 12,835 million yen. The
main account of cash outflow was payment of corporate income tax, 9,868 million yen.
(Cash flows from investing activities)
Net cash used in investing activities was 13,275 million yen. The main account of cash inflow was proceeds fromwithdrawal of time deposits, 7,788 million yen. The main accounts of cash outflow were purchase of noncurrent assets,
18,371 million yen.
(Cash flows from financing activities)
Net cash provided by financing activities was 24,727 million yen. The main account of cash inflow was proceeds fromlong-term loans payable, 55,539 million yen. The main account of cash outflow was repayment of long-term loans
payable, 28,155 million yen.

(3) Commentary on Forward-Looking Statements Including Forecast of Consolidated Financial Results
We expect that the global economy will continue to be on the gradual recovery trend. Similarly, in Japan, economic
activities will continue to gradually improve amid the easing of the fallback after the last-minute surge in demand before theconsumption tax rate hike.
Even under such circumstances, the Nipro Group will work to improve profits through its continued efforts to expand
sales and reduce production costs.
We have revised the forecast of consolidated financial results for the year ending March 31, 2015, which wasannounced on August 12, 2014, based on the current movement in performance.

2. Summary (Other) Information(1) Changes in Significant Consolidated Subsidiaries
N/A(2) Accounting Treatments Simplified or Unique for Preparation
N/A(3) Changes in Accounting Policies and Accounting Estimate and Restatement(Change in Accounting Policies)
Application of the Accounting Standard for Retirement Benefits and its Guidance
From the first quarter of the consolidated fiscal year under review, we adopted the “Accounting Standard for
Retirement Benefits” (ASBJ Statement No. 26, May 17, 2012; hereinafter referred to as the “Retirement Benefits
Standard”) and the “Guidance on Accounting Standard for Retirement Benefits” (ASBJ Guidance No. 25, May 17, 2012;
hereinafter referred to as the “Retirement Benefits Guidance”) with regard to the provisions specified under the main clause-4-

of paragraph 35 of the Retirement Benefits Standard and paragraph 67 of the Retirement Benefits Guidance. The
calculation method of retirement benefit obligations and service costs was reviewed, the period attribution method of the
expected amount of retirement benefits was changed from a straight‐line attribution to a benefit calculation standard andthe decision method of the discount rate was changed from the way in which the number of years approximate to theaverage remaining service period of employees is used for the period of bonds that serves as thebasis for determining

the discount rate to the way in which a single weighted average discount rate is used to reflect the expected payment
period of retirement benefits and the amount for each expected payment period.
In applying the Retirement Benefits Standard and its Guidance, the effect of the changes in the calculation method ofretirement benefit obligations and service costs was adjusted in retained earnings at the beginning of the first quarter of theconsolidated fiscal year under review according to the transitional treatment set forth in the paragraph 37 of the Retirement
Benefits Standard.
As a result, net defined benefit liability decreased 150 million yen and retained earnings increased 97 million yen at the
beginning of the current quarterly period under review. This change had no impact on operaing income, ordinary income andincome before income taxes and minority interests in the current quarterly period under review.

-5-3. Consolidated Financial Statements(1) [ Quarterly Consolidated Balance Sheets](Millions of yen)
As ofMarch 31, 2014
AssetsCurrent Assets
Cash and deposits
Notes and accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Deferred tax assets
Other
Allowance for doubtful accounts
Total current assets
Noncurrent assets
Property, plant and equipment
Bulidings and structures
Accumulated depreciation and impairment loss
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation and impairment loss
Machinery equipment and vehicles, net
Land
Lease assets
Accumulated depreciation
Lease assets, net
Construction in progress
Other
Accumulated depreciation and impairment loss
Other, net
Total property, plant and equipment
Intangible assets
Goodwill
Lease assets
Other
Total intangible assets
Investments and other assets
Investment securities
Net defined benefit asset
Deferred tax assets
Other
Allowance for doubtful accounts
Total investments and other assets
Total noncurrent assets
Total assets

-6-

As of
September 30, 2014

84,957103,179
59,517
10,96820,0007,354
12,154(2,010)296,119

99,871
104,755
62,133
10,411
20,818
5,705
14,578(2,040)316,233

158,109(77,025)
81,083
192,277(135,012)
57,26523,3672,409(1,507)902
20,53437,683(29,242)8,440
191,593

163,935(77,637)
86,298
196,715(139,937)
56,778
21,104
2,239(1,577)662
23,29538,961(30,378)
8,583
196,72128,493443
13,27842,21627,922372
14,337
42,63365,50798
8,453
18,535(2,870)89,724
323,534
619,654

60,001
103
9,211
11,579(2,909)77,986317,341
633,574(Millions of yen)
As ofMarch 31, 2013
Liabilities
Current liabilities
Notes and accounts payable-trade
Short-term loans payable
Commercial papers
Current portion of bonds
Current portion of convertible bond-type bonds
with subscription rights to shares
Lease obligations
Accounts payable-otherAccrued directors' bounuses
Income taxes payable
Provision for bounuses
Provision for directors' bounuses
Provision for loss on business liquidation
Notes payable-facilities
Other
Total current liabilities
Noncurrent liabilities
Bonds payable
Long-term loans payable
Lease obligations
Deferred tax liabilities
Net defined benefit liability
Provision for directors' retirement benefits
Provision for loss on litigation
Other
Total noncurrent liabilities
Total liabilities
Net assets
Shareholders' equity
Capital stock
Capital surplus
Retained earnings
Treasury stock
Total shareholders' equity
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Deferred gains or losses on hedges
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Total accumulated other comprehensive income
Minority interests
Total net assets
Total liabilities and net assets

-7-

As of
September 30, 2014

45,661
127,384
10,0004,315

47,718126,305
10,0001,905

14,895

12,420

949
8,563
415
10,734
3,516
123
2,438
2,897
18,820250,714

706
7,345
－
4,558
3,350
249
－
5,878
14,249234,687

45,832
177,004
1,510
1,976
4,042
449
284
1,878
232,979
483,694

44,375
208,317
1,352
2,019
3,924
466
276
2,124
262,856
497,544

84,397688
52,567(17,999)
119,654

84,397635
55,489(15,246)
125,276(7,443)38
13,535(357)
5,772
10,533
135,960
619,654(8,099)
(45)
8,735
(306)
283
10,469136,029
633,574(2) [Quarterly Consolidated Statements of Income and Quarterly Consolidated Statement of Comprehensive Income]Quarterly Consolidated Statements of Income(Amount: million yen)
FY2013 first three months(From April 1, 2013
to September 30, 2013)
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating income
Non-operating income
Interest income
Dividends income
Foreign exchange gain
Other
Total non-operating income
Non-operating expenses
Interest expenses
Equity in losses of affiliates
Other
Total non-operating expenses
Ordinary income
Extraordinary income
Gain on sales of noncurrent assets
State subsidy
Gain on sales of investment securities
Compensation income
Other
Total extraordinary income
Extraordinary loss
Loss on retirement of noncurrent assets
Loss on valuation of investment securities
Loss on sales of investment securities
Loss on reduction of non-current assets
Other
Total extraordinary losses
Income before income taxes and minority interests
Income taxes-current
Income taxes-deferred
Total income taxes
Income before minority interests
Minority interests in income
Net income

FY2014 first three months(From April 1, 2014
to September 30, 2014)

143,407
101,691
41,71535,918
5,797

154,501
107,832
46,66838,728
7,939

415
942
589
668
2,615

362
829
1,940
1,012
4,144

1,988
－
636
2,625
5,787

2,027
80
1,356
3,465
8,618

203
544
18
735
305
1,807

27
－
3,402
33
20
3,483

32
10
－
530
191
765
6,829
5,324
(1,222)
4,102
2,727
107
2,619

38
0
1,233
－
33
1,305
10,796
4,119
1,032
5,152
5,644
174
5,470

[Qarterly Consolidated Statements of Comprehensive Income](Amount: million yen)
FY2013 first three months(From April 1, 2013
to September 30, 2013)
Income before minority interests
Other comprehensive income
Valuation difference on available-for-sale securities
Deferred gains or losses on hedges
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to owners of the parent
Comprehensive income attributable to minority interests-8-

FY2014 first three months(From April 1, 2014
to September 30, 2014)

2,727

5,644

9,407
－
13,891－
23,29826,02525,086
938

(654)
(84)
(5,166)50(5,854)
(209)
(18)
(190)

(3) [ Quarterly Consolidated Statements of Cash Flows]

FY2013 first three months(From April 1, 2013
to September 30, 2013)
Net cash provided by (used in) operating activities
Income before income taxes and minority interests
Depreciation and amortization
Impairment loss
Amortization of goodwill
Equity in (earnings) losses of affiliates
Increase (decrease) in allowance for doubtful accounts
Increase (decrease) in provision for retirement benefits
Increase (decrease) in ｎet defined benefit liability
Interest and dividends income
Interest expenses
Foreign exchange losses (gains)
Loss (gain) on sales of investment securities
Decrease (increase) in notes and accounts receivable-trade
Decrease (increase) in inventories
Increase (decrease) in notes and accounts payable-trade
Decrease (increase) in other assets
Increase (decrease) in other liabilities
Other loss (gain)
SubtotalInterest and dividends income received
Interest expenses paid
Other proceeds
Other payments
Income taxes paid
Net cash provided by (use in) operating activities
Net cash provided by (used in) investing activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of investment securities
Proceeds from sales of investment securities
Payments for sales of investments
in subsidiaries resulting in change in scope of consolidation
Payments for investments in capital
Purchase of noncurrent assets
Proceeds from sales of noncurrent assets
Payments for retirement of noncurrent assets
Proceeds from capital investment subsidies received
Net decrease (increase) in short-term loans receivable
Payments of loans receivableCollection of loans receivable
Other payments
Other proceeds
Net cash provided by (use in) investment activities-9-(Amount: million yen)
FY2014 first three months(From April 1, 2014
to September 30, 2014)

6,829
11,948
1
2,354
－
38
146
－
(1,357)
1,988(2,011)(18)(2,993)(439)(3,054)(117)(1,892)(64)
11,3581,284(2,020)439(435)(4,177)
6,449

10,796
12,835
12
2,598
80
102
－
114
(1,191)
2,027(697)(2,169)(3,004)(3,954)
3,110(3,456)(3,684)(254)
13,2671,131(2,048)140(145)(9,868)2,476(2,589)731(3,169)75(8,706)
7,788(1,484)
6,227(5,612)(751)(1,407)(14,662)
351
(1)
609
(138)
(114)
55
(13)
1
(25,883)－(18,371)
2,094
(9)
－
(14)
(146)
82
－
16
(13,275)

FY2013 first three months(From April 1, 2013
to September 30, 2013)
Net cash provided by (use in) financial activities
Net increase (decrease) in short-term loans payable
Proceeds from long-term loans payable
Repayment of long-term loans payable
Redemption of bonds
Proceeds from stock issuance to minority shareholders
Decrease (increase) in treasury stock
Proceeds from sales of treasury shares
Purchase of treasury shares
Repayments of finance lease obligations
Cash dividends paid
Cash dividends paid to minority shareholders
Net cash provided by (use in) financing activities
Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of paid
Increase in cash and cash equivalentsfrom newly consolidated subsidiary
Cash and cash equivalents at end of period- 10 -(Amount: million yen)
FY2014 first three months(From April 1, 2014
to September 30, 2014)

16,721
19,125(26,952)(588)
153(17,196)－－(663)(2,638)(10)(12,050)
3,782(27,702)
92,622

3,962
55,539(28,155)(3,867)
－
－
108
(0)
(634)
(2,204)(20)
24,727(103)
13,82470,892

19

655

64,94085,372

(3) Notes Regarding Consolidated Financial Statement(Notes regarding going concern)
N/A(Notes regarding significant changes in the amount of shareholders’ equity)
N/A(Segment Information)Ⅰ

FY2013 (From April 1, 2013 to September 30, 2013)

1.

Sales and Profit by Reportable Operating Segment(Millions of yen)Segment
MedicalRelated

PharmaceuticalRelated

GlassRelated

Total

Other
(Note.1)

Total

Adjustment(Note.2)

Consolidated
Statements ofIncome(Note.3)

Net sales(1)Sales to third parties

105,162

24,25913,868143,289

117

143,407－

143,407(2)Inter-segment sales
and transfers

635

3,710

276

4,621

19

4,641

(4,641)－

Total

105,797

27,96914,144

147,911136

148,048(4,641)

143,407

Segment profit

9,444

3,798

(1,294)

11,949109

12,058(6,260)5,797(Notes)
1.
2.

3.
2.

“Other” is the business segment which is not included in the segment and consist of real estate income and sales
by headquarter.
Adjustment for the segment profit of (6,260) million yen includes elimination of inter-segment transaction of(1,215) million yen and corporate cost of (5,045) million yen. Corporate cost consisted primarily of general andadministrative expenses and research and development cost which do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

Information about Impairment Loss on Fixed Assets and Goodwill by Reportable Operating Segment(Significant Change in Goodwill)
Regarding Medical-Related Business, we acquired the share of Nichihos Co., Ltd. and its 10 subsidiaries toinclude them in the scope of consolidation. In accordance with it, goodwill increased 6,851million yen from the endof the previous year.

- 11 -

Ⅱ

FY2014 (From April 1, 2014 to September 30, 2014)

1.

Sales and Profit by Reportable Operating Segment(Millions of yen)Segment
MedicalRelated

PharmaceuticalRelated

GlassRelated

Total

Other
(Note.1)

Total

Adjustment(Note.2)

Consolidated
Statements ofIncome(Note.3)

Net sales(1)Sales to third parties

112,538

27,775

14,124

154,437

63

154,501－

154,501(2)Inter-segment sales
and transfers

788

4,100

322

5,211

17

5,229

(5,229)－Total

113,326

31,875

14,447

156,64980

159,730(5,229)154,501

Segment profit

11,1544,860(1,603)

14,41176

14,488(6,548)

7,939(Notes)4.
5.

6.

“Other” is the business segment which is not included in the segment and consist of real estate income and sales
by headquarter.
Adjustment for the segment profit of (6,548) million yen includes elimination of inter-segment transaction of(1,232) million yen and corporate cost of (5,316) million yen. Corporate cost consisted primarily of general andadministrative expenses and research and development cost which do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

2. Changes in Reportable Segments(1) Effective from this reporting period, Nipro Glass India PVT. LTD., Nipro Tube Glass PVT. LTD., Nipro Glass Americas
Corporation, Nipro Glass France S.A.S., Nipro Glass Belgium N.V., Nipro Pharma Glass AG, Nipro Glass Germany AG,
Nipro Sterile Glass Germany AG, Chengdu Pingyuan Nipro Pharmaceutical Packaging Co., Ltd., Jilin Nipro Jiaheng
Pharmaceutical Packaging Co., Ltd. and Anyang Nipro Changda Pharmaceutical Packaging Co., Ltd. are reclassified
from Medical-Related Business to Glass-Related Business with current review of organization system in Nipro group.
(2) Effective from the first period ended June 30, 2014, the calculation method of retirement benefit obligations and service
costs in business segment was changed following the changes in accounting policy.
This change had no impact to profit and loss.
3. Information on Impairment Loss on Fixed Assets and on Goodwill by Reportable Segment
N/A- 12 -